Background: Patients with inflammatory bowel disease (IBD) post-liver transplant (LT) may have bowel inflammation requiring biologic therapy. We aimed to evaluate the safety of combination biologic and antirejection therapy in IBD patients after LT from a tertiary center case series and an updated literature review.


Adverse Effects, Immunosuppression Therapy, Complications, Etiology, Liver Transplant, Inflammatory Bowel Disease, Cholangitis, IBD, Sclerosing, Crohn's Disease, Clostridium Infections, Ulcerative Colitis, Liver Transplantation, therapeutic use, Biological Products

Read More